Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

android tablet pc

Home > Press > Combination of Introgenís Nanoparticles Demonstrate Increased Efficacy in the Treatment of Metastatic Lung Cancer

Two powerful tumor suppressor genes, p53 and FUS1, administered intravenously in nanoparticle formulations were capable of significantly shrinking metastatic tumors in models of human lung cancer, according to investigators at The University of Texas M. D. Anderson Cancer Center. Molecular cancer therapies using these genes, p53 and FUS1, are in clinical-stage development by Introgen Therapeutics (NASDAQ:INGN). The technologies are included in a broad portfolio of intellectual properties licensed exclusively to Introgen from M. D. Anderson Cancer Center and other institutions.

Combination of Introgenís Nanoparticles Demonstrate Increased Efficacy in the Treatment of Metastatic Lung Cancer

AUSTIN, Texas | Posted on January 16th, 2007

The study, published in the January 15 issue of the journal Cancer Research, found that each of the nanoparticle tumor suppressors was effective therapy but more powerful results were observed when the treatments were combined. Systemic therapy with combined p53 and FUS1 nanoparticles in disseminated, metastatic lung cancers decreased the number of human lung tumors by 75 percent and cut their size by 80 percent. The studies also showed that the nanoparticle treatments had no demonstrable adverse effects on normal cells.

Abnormalities of the p53 and FUS1 tumor suppressors are among the most common molecular defects found in human cancers. The mechanism of the increased activity of the combined therapy was determined. The restoration of FUS1 function prevented the breakdown of the administered p53 resulting in its increased ability to destroy tumor cells.

This novel treatment strategy − the first time that two functional tumor suppressor genes have been used in a nanoparticle treatment − may offer a promising clinical treatment for lung and other cancers, according to lead author Lin Ji, Ph.D., assistant professor in the Department of Thoracic & Cardiovascular Surgery research at M. D. Anderson.

Robert E. Sobol, M.D., Introgen's senior vice president, Medical and Scientific Affairs stated, "These results further support our continued clinical development of p53 and FUS1 tumor suppressor therapies. These nanoparticle formulations facilitate treatment of disseminated cancers and validate the important concept of combining tumor suppressors selected to work synergistically in killing cancer cells while leaving normal cells unharmed."

In this study, the researchers tested the combined FUS1/p53 nanoparticles against four different human lung cancers as well as in normal non-cancerous cells. The treatment dramatically inhibited tumor cell growth in all four lung cancers tested, they said. It also induced cell death in the tumors, likely through the activation of p53 and FUS1 mediated gene functions that resulted in the killing of cancer cells but not normal cells.


About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be ďforward-lookingĒ statements, including those relating to Introgenís future success with its clinical development program with p53 and FUS1 for treatment of cancer or other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgenís operations and business environment, including Introgenís stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgenís product candidates, the ability to obtain the appropriate regulatory approvals, Introgenís patent protection and market acceptance, as well as other risks detailed from time to time in Introgenís filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editorís Note: M. D. Anderson Cancer Center also issued a news release about this publication. It may be found at .

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgenís Website at: .

For more information, please click here

Introgen Therapeutics, Inc.
C. Channing Burke, 512-708-9310 Ext. 322

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014


Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

Iranian, Malaysian Scientists Study Nanophotocatalysts for Water Purification October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014


Nanoparticle technology triples the production of biogas October 23rd, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Advancing thin film research with nanostructured AZO: Innovnanoís unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Human Interest/Art

Iran-Made Respiratory Nano Masks Provided to Hajj Pilgrims October 23rd, 2014

Japanese gold leaf artists worked on a nano-scale: Study demonstrates X-ray fluorescence spectroscopy is a non-destructive way to date artwork July 3rd, 2014

Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013

Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE